

***Assessment Methods and Endpoints for Rapid Acting Antidepressants (RAADs) Working Group
26 October 2020***

In this meeting of the working group we reviewed the draft consensus statement on the type and manner of assessments appropriate for this class of compounds. The crystallization of the consensus statement is the platform for the development of a review paper and our aim during the meeting was to identify key contributors and establish timelines for the writing, review and submission of this paper.

The working group draft consensus statement includes those categories previously identified during previous groups as essential for assessment:

- Use of existing scales (e.g., adapted MADRS)
- Development and implementation of appropriate biomarkers (digital, biologic or imaging) to assess rapid change in symptoms
- Transdiagnostic assessment

Additionally, we discussed pooling scale data from across RAAD studies classified by mechanism of action from pharmaceutical partners in order to conduct analyses to determine the item and scale-based characteristics that will be the most salient measures moving forward.

After the meeting, a survey was distributed to working group members to identify volunteers and leaders for each manuscript subgroup topic. Once identified, those groups will meet to discuss next steps.